Overview
Vasculitic neuropathy (VN) involves inflammation of blood vessels leading to peripheral nerve injury, often presenting as axonal sensorimotor neuropathy, frequently affecting the tibial and peroneal nerves. It can be systemic or non-systemic, with diverse underlying causes including primary vasculitides like eosinophilic granulomatosis with polyangiitis (EGPA) 1.Diagnosis
Clinical Presentation: Typically subacute onset with painful mononeuropathies or asymmetric polyneuropathy 3.
Histopathological Features: Nerve biopsy essential; shows transmural inflammatory cell infiltration (ICI) more frequently in systemic VN 1.
Immunohistochemistry: Hypoxia-inducible factor 1alpha (HIF-1alpha) expression in endoneurial cells can aid diagnosis, distinguishing VN from other axonal neuropathies 2.
Biopsy Findings: Increased MMP-9 expression in perivascular infiltrates supports diagnosis 4.
Differential Diagnosis: Distinguish from Guillain-Barré syndrome (GBS) through histological examination 5.
Complement Analysis: Hypocomplementemia and specific complement deficiencies may indicate hypocomplementemic vasculitic urticarial syndrome 7.Management
First-Line Treatments: Corticosteroids are foundational, often combined with cytotoxic drugs 3.
Adjunctive Therapies: Intravenous immunoglobulin and biological agents show promise but require further trials 3.
Monitoring: Regular assessment for thrombosis, especially in systemic vasculitic neuropathy with ICI 1.
Dosing and Side Effects: Specific dosing details vary; manage potential side effects of corticosteroids and cytotoxic agents carefully 3.Special Populations
Pregnancy: Specific management guidelines not detailed in provided abstracts 3.
Elderly: Increased vulnerability to severe distal weakness and complications like thrombosis noted 1.
Comorbidities: No specific guidance provided in abstracts; general principles likely apply 3.Key Recommendations
Perform nerve biopsy for definitive diagnosis, especially to identify transmural inflammatory cell infiltration 1 (Evidence: Strong).
Initiate treatment with corticosteroids as first-line therapy for vasculitic neuropathy 3 (Evidence: Strong).
Consider HIF-1alpha expression in nerve biopsies to aid in distinguishing vasculitic neuropathy from other axonal neuropathies 2 (Evidence: Moderate).
Monitor for thrombotic complications particularly in systemic vasculitic neuropathy with transmural inflammation 1 (Evidence: Moderate).
Evaluate complement levels in patients with persistent urticaria, angioedema, and neurological symptoms to rule out hypocomplementemic vasculitic urticarial syndrome 7 (Evidence: Weak).References
1 Zhou X, Shan D, Wu B, Liu F, Zhang D, Lin P et al.. Clinical and Pathological Features of Vasculitic Neuropathy: A Single-Center Study in China. European journal of neurology 2026. link
2 Oka N, Kawasaki T, Mizutani K, Sugiyama H, Akiguchi I. Hypoxia-inducible factor 1alpha may be a marker for vasculitic neuropathy. Neuropathology : official journal of the Japanese Society of Neuropathology 2007. link
3 Schaublin GA, Michet CJ, Dyck PJ, Burns TM. An update on the classification and treatment of vasculitic neuropathy. The Lancet. Neurology 2005. link70249-0)
4 Gurer G, Erdem S, Kocaefe C, Ozgüç M, Tan E. Expression of matrix metalloproteinases in vasculitic neuropathy. Rheumatology international 2004. link
5 Suggs SP, Thomas TD, Joy JL, Lopez-Mendez A, Oh SJ. Vasculitic neuropathy mimicking Guillain-Barré syndrome. Arthritis and rheumatism 1992. link
6 Fujimura H, Lacroix C, Said G. Vulnerability of nerve fibres to ischaemia. A quantitative light and electron microscope study. Brain : a journal of neurology 1991. link
7 Zeiss CR, Burch FX, Marder RJ, Furey NL, Schmid FR, Gewurz H. A hypocomplementemic vasculitic urticarial syndrome. Report of four new cases and definition of the disease. The American journal of medicine 1980. link90216-8)